|1.||Unzeta, Mercedes: 6 articles (01/2014 - 07/2010)|
|2.||Solé, Montse: 6 articles (01/2014 - 07/2010)|
|3.||Jalkanen, Sirpa: 3 articles (11/2014 - 04/2004)|
|4.||Mátyus, Péter: 3 articles (06/2013 - 12/2010)|
|5.||Salmi, Marko: 2 articles (11/2014 - 06/2011)|
|6.||Wei, Jung-Nan: 2 articles (07/2014 - 05/2009)|
|7.||Chuang, Lee-Ming: 2 articles (07/2014 - 05/2009)|
|8.||Li, Hung-Yuan: 2 articles (07/2014 - 05/2009)|
|9.||Sun, Ping: 2 articles (01/2014 - 06/2013)|
|10.||Tábi, Tamás: 2 articles (06/2013 - 06/2013)|
03/01/2004 - "By releasing VAP-1/SSAO, adipose cells could contribute to the atherogenesis and vascular dysfunction associated with diabetes and obesity."
04/01/2004 - "These findings suggest that, although manipulation of VAP-1/SSAO has potential to serve as a therapeutic treatment in insulin-resistant conditions, care must be taken to fully understand its impact on obesity and vascular damage."
06/01/2005 - "The aim of this work was to complete a preceding study where we described the role played by some hormones or metabolites, implicated in diabetes and/or obesity, in the regulation of the release of VAP-1/SSAO by 3T3-L1 adipocytes. "
06/01/2005 - "Plasma level of the protein VAP-1/SSAO (Vascular Adhesion Protein-1/Semicarbazide-Sensitive Amine Oxidase) is increased in diabetes and/or obesity and may be related to vascular complications associated to these pathologies. "
06/01/2013 - "However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization."
06/01/2013 - "At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). "
06/01/2013 - "Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model."
06/01/2013 - "The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. "
07/01/2010 - "Our data demonstrate that baseline VAP-1/SSAO activity predicts parenchymal hemorrhage after tPA, suggesting the safety of thrombolytic agents could be improved by considering VAP-1/SSAO activity. "
07/01/2010 - "We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment. "
01/01/2014 - "The aim of this study has been to elucidate the role of SSAO/VAP-1 present in endothelial cells during ischemic stroke conditions. "
01/01/2014 - "For all the stroke-related processes in which SSAO/VAP-1 participates, it would be an interesting therapeutic target. "
01/01/2014 - "Our results show that SSAO/VAP-1 could participate in some of the processes occurring during stroke. "
01/01/2012 - "Plasma VAP-1/SSAO activity <2.7 pmol/min·mg and baseline ICH volume <17 ml were independent predictors of neurological improvement after 48 h (OR 6.8, 95% CI 1.14-41.67, p = 0.035, and OR 10.64, 95% CI 1.1-100, p = 0.041, respectively), after adjustment for baseline stroke severity. "
01/01/2012 - "In addition, we assessed the expression of VAP-1/SSAO in postmortem brain tissue from hemorrhagic stroke patients by Western blot and immunohistochemistry. "
|5.||Alzheimer Disease (Alzheimer's Disease)
06/01/2013 - "The combined inhibition of SSAO/VAP-1, MAO (A and B), AChE and BuChE appear as an important therapeutic target to be considered in the treatment of cerebrovascular and neurological disorders such as Alzheimer's disease."
10/01/2012 - "Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) is involved in vascular endothelial damage as well as in the vascular degeneration underlying diabetes mellitus and Alzheimer's disease (AD). "
02/01/2012 - "The aim of this study was to evaluate the effect of some synthetic polyamines as inhibitors of two new potential targets, human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) and monoamine oxidases B (MAO B), enzymes involved in various multi-factorial diseases such as Alzheimer's disease. "
|1.||Amine Oxidase (Copper-Containing)
|4.||Fibrinolytic Agents (Antithrombotic Agents)
|6.||Monoamine Oxidase (MAO)
|8.||Tissue Plasminogen Activator (Alteplase)